The increasing evidence indicating the protective properties of ADM on reducing endothelial permeability and improving endothelial stability and microcirculation, thereby reducing organ damage, as well as its anti-microbial activity, has prompted several clinical trials in sepsis and heart failure to investigate the potential therapeutic use of antibodies, such as adrecizumab targeting ADM. This evidence concerns the gene ADM and Sepsis.